Trinity Biotech Appoints New Chief Commercial Officer
Ticker: TRIB · Form: 6-K · Filed: Sep 4, 2024 · CIK: 888721
| Field | Detail |
|---|---|
| Company | Trinity Biotech PLC (TRIB) |
| Form Type | 6-K |
| Filed Date | Sep 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change
TL;DR
Trinity Biotech just hired a new Chief Commercial Officer, Adrian Donohue.
AI Summary
Trinity Biotech PLC announced on September 3, 2024, the appointment of Adrian Donohue as its new Chief Commercial Officer. Donohue brings global life sciences leadership experience to the role.
Why It Matters
The appointment of a new Chief Commercial Officer is a key leadership change that could impact the company's commercial strategy and future growth.
Risk Assessment
Risk Level: low — This filing is a routine announcement of an executive appointment and does not contain significant financial or operational news.
Key Players & Entities
- Trinity Biotech PLC (company) — Registrant
- Adrian Donohue (person) — Appointed Chief Commercial Officer
- September 3, 2024 (date) — Date of press release
FAQ
Who has been appointed as the new Chief Commercial Officer of Trinity Biotech PLC?
Adrian Donohue has been appointed as the new Chief Commercial Officer.
When was the appointment of the new Chief Commercial Officer announced?
The appointment was announced on September 3, 2024.
What is the principal executive office address of Trinity Biotech PLC?
The principal executive office is located at IDA Business Park, Bray, County Wicklow, Ireland.
Does Trinity Biotech PLC file annual reports under Form 20-F or Form 40-F?
Trinity Biotech PLC files annual reports under Form 20-F.
What exhibit is being furnished with this 6-K filing?
Exhibit 99.1, a press release announcing the appointment of Adrian Donohue, is being furnished with this filing.
Filing Stats: 180 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-09-04 11:59:56
Filing Documents
- zk2431986.htm (6-K) — 18KB
- exhibit_99-1.htm (EX-99.1) — 13KB
- image1.jpg (GRAPHIC) — 90KB
- 0001178913-24-002947.txt ( ) — 156KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC Trinity Biotech plc (Registrant) By: /s/ Louise Tallon Louise Tallon Chief Financial Officer Date: September 4, 2024